Eneapharm

Eneapharm is a clinical-stage biopharmaceutical company based in the Toulouse Oncopole region of France. The company focuses on developing innovative therapeutic solutions for Exocrine Pancreatic Insufficiency (EPI), a condition where the pancreas does not produce enough enzymes to digest food properly. Eneapharm's proprietary technology platform enables the development of specialized enzymatic delivery formats designed to restore digestive assimilation. Their pipeline targets high-unmet-need populations, including patients with cystic fibrosis, pancreatic cancer, Crohn's disease, and chronic alcoholism, where current treatments are often inadequate or difficult to administer.